feed,title,long_url,short_url
Benzinga,"Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst",https://benzinga.com/general/biotech/23/12/36044511/weight-loss-drugs-novo-nordisk-a-primary-beneficiary-in-obesity-space-currently-controlled-by-two,https://da.gd/IFCD
